Curis Inc (CRIS) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 7, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 14, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the CRIS SEC filings page.
Curis Inc (CRIS) reported $4.3M in revenue over the twelve months to Jun 30, 2026, down 62.2% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Curis’s reported business remains development-stage: research spending is several times revenue, while operations still depend on financing beyond current receipts.
FY2025’s operating loss narrowed to$5.7M from$44.5M as revenue slipped, so the improvement came from cost reduction rather than sales expansion. With R&D still nearly 3x revenue, operating cash flow of-$27.2M shows that a smaller reported loss has not yet become self-funding operations.
R&D remained nearly 3x revenue in FY2025, making current economics depend more on development investment than commercial receipts. Because R&D fell alongside the operating loss, the year’s improvement is best read as a reduced investment burden, not evidence that revenue now supports the cost base.
The balance sheet is short-term tight: a 0.5x current ratio means current assets were below current liabilities, limiting financial flexibility. Reported liquidity measured 2.2 months of latest annual operating outflow, while financing supplied
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Curis Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Curis Inc held $5.1M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $27.2M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Curis Inc scores 10/100 among other emerging companies.
Curis Inc had 40M shares outstanding at the end of fiscal year 2025. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and Curis Inc scores 7/100 among other emerging companies.
Curis Inc spent $28.3M on research and development in fiscal year 2025, which was 186.4% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Curis Inc scores 100/100 among other emerging companies.
Curis Inc reported revenue of $9.4M in fiscal year 2025, against $10.9M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and Curis Inc scores 39/100 among other emerging companies.
Curis Inc's operations used $27.2M of cash in fiscal year 2025, against $39.6M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and Curis Inc scores 61/100 among other emerging companies.
Curis Inc's cash, cash equivalents and investments came to $5.1M at the end of fiscal year 2025, against $14.5M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Curis Inc scores 36/100 among other emerging companies.
Curis Inc scores -88.29, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($1.8M) relative to total liabilities ($14.5M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Curis Inc passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
Curis Inc reported a net loss of $7.6M while operations used $27.2M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Curis Inc generated $0 in revenue in Q2 2026. This represents a decrease of 100.0% from the same quarter a year earlier.
Curis Inc's EBITDA was -$9.9M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 21.0% from the same quarter a year earlier. Against the prior quarter it is up 13.7%.
Curis Inc reported -$8.6M in net income in Q2 2026. This represents an increase of 0.1% from the same quarter a year earlier. Against the prior quarter it is up 64.5%.
Cash & Balance Sheet
Curis Inc held $5.1M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
Curis Inc's ROE was -182.8% in Q2 2026, measuring profit generated per dollar of shareholder equity. Against the prior quarter it is up 7.7 percentage points.
Not reported for Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Capital Allocation
Curis Inc invested $6.7M in research and development in Q2 2026. This represents a decrease of 10.0% from the same quarter a year earlier. Against the prior quarter it is up 4.1%.
Not reported for Q2 2026.
Not reported for Q2 2026.
CRIS Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0-100.0% | $0-100.0% | $1.1M-66.0% | $3.2M+8.4% | $2.7M+8.0% | $2.4M+14.1% | $3.3M+24.1% | $2.9M+3.5% |
| R&D Expenses | $6.7M-10.0% | $6.4M-24.5% | $5.8M-35.0% | $6.4M-33.8% | $7.5M-27.3% | $8.5M-11.2% | $9.0M-10.0% | $9.7M-6.3% |
| SG&A Expenses | $3.2M-8.5% | $5.1M+27.3% | $2.9M-14.0% | $3.7M-2.7% | $3.5M-26.4% | $4.0M-18.5% | $3.4M-31.2% | $3.8M-21.2% |
| Operating Income | -$9.9M-20.5% | -$11.5M-13.4% | $19.6M+318.1% | -$6.9M+34.5% | -$8.3M+34.1% | -$10.2M+18.5% | -$9.0M+26.3% | -$10.6M+14.6% |
| EBITDA | -$9.9M-21.0% | -$11.5M-14.0% | $19.7M+318.9% | -$6.9M+34.4% | -$8.2M+34.1% | -$10.1M+18.6% | -$9.0M+26.0% | -$10.5M+14.6% |
| Net Income | -$8.6M+0.1% | -$24.2M-127.9% | $19.4M+301.2% | -$7.7M+23.4% | -$8.6M+27.2% | -$10.6M+10.6% | -$9.6M+17.9% | -$10.1M+17.1% |
| EPS (Basic) | -$4.02+70.5% | -$1.250.0% | $1.61+245.0% | -$0.49+71.2% | -$13.61-570.4% | -$1.25+39.0% | -$1.11+44.5% | -$1.70+20.2% |
| EPS (Diluted) | -$4.02 | -$1.25 | $1.61 | -$0.49 | -$13.61 | -$1.25+39.0% | -$1.11+44.5% | -$1.70+20.2% |
| Diluted Shares (Avg) | 2M | 19M | N/A | 16M | 631,475 | 8M+46.9% | N/A | 6M+3.8% |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Interest Expense, Income Tax.
CRIS Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $19.0M-35.1% | $29.7M-24.5% | $20.0M-51.6% | $27.6M-34.9% | $29.2M-42.0% | $39.3M-36.6% | $41.3M-46.6% | $42.5M-52.8% |
| Current Assets | $6.7M-53.4% | $16.6M-33.0% | $6.9M-73.8% | $13.9M-48.4% | $14.4M-58.2% | $24.8M-46.1% | $26.4M-56.7% | $26.9M-63.3% |
| Cash & Equivalents | $5.1M-50.0% | $15.0M-26.0% | $5.1M-74.7% | $9.1M-56.6% | $10.1M+1.4% | $20.3M-32.3% | $20.0M-25.1% | $20.9M-14.8% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0-100.0% | $0-100.0% | $0-100.0% | $0-100.0% |
| Accounts Receivable | N/A | N/A | $0-100.0% | $3.2M+8.9% | $2.8M+8.1% | $2.3M+7.5% | $3.3M+19.9% | $3.0M+4.6% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill | $9.0M0.0% | $9.0M0.0% | $9.0M0.0% | $9.0M0.0% | $9.0M0.0% | $9.0M0.0% | $9.0M0.0% | $9.0M0.0% |
| Total Liabilities | $14.3M-67.0% | $17.0M-63.0% | $14.5M-69.3% | $42.3M-17.3% | $43.2M-15.4% | $45.9M-12.6% | $47.3M-18.0% | $51.2M-15.2% |
| Current Liabilities | $13.7M-29.4% | $15.0M-25.6% | $14.1M-26.0% | $19.9M-9.6% | $19.4M0.0% | $20.1M+78.0% | $19.0M-13.6% | $22.0M+60.7% |
| Non-Current Liabilities | $600K-97.5% | $2.0M-92.2% | $428K-98.5% | $22.4M-23.2% | $23.8M-24.9% | $25.8M-37.4% | $28.2M-20.7% | $29.2M-37.5% |
| Total Equity | $4.7M+133.6% | $12.7M+292.3% | $5.5M+191.1% | -$14.7M-68.2% | -$14.0M-1915.3% | -$6.6M-169.8% | -$6.0M-130.5% | -$8.7M-129.5% |
| Retained Earnings | -$1.3B-1.7% | -$1.3B-1.7% | -$1.2B-0.6% | -$1.3B-3.0% | -$1.3B-3.2% | -$1.3B-3.5% | -$1.2B-3.6% | -$1.2B-3.8% |
Not reported in any period shown, so not listed: Inventory, Long-Term Debt.
CRIS Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$9.6M-20.4% | -$9.0M-24.1% | -$6.4M+31.2% | -$5.6M+6.2% | -$8.0M+28.1% | -$7.3M+45.2% | -$9.3M+9.1% | -$5.9M+27.4% |
| Depreciation & Amortization | $8K-81.0% | $8K-86.4% | $36K+125.0% | $32K-47.5% | $42K-32.3% | $59K-7.8% | $16K-75.0% | $61K-3.2% |
| Stock-Based Compensation | $569K-49.9% | $575K-50.6% | N/A | $924K-33.2% | $1.1M-33.4% | $1.2M-25.3% | N/A | $1.4M-15.2% |
| Investing Cash Flow | $0 | $0 | $2.5M+684.1% | $0-100.0% | $0+100.0% | $0-100.0% | -$428K-102.9% | $18.3M+10076.7% |
| Financing Cash Flow | -$282K+86.8% | $18.9M+151.3% | -$119K-101.3% | $4.5M+394.1% | -$2.1M-45.8% | $7.5M+413.3% | $8.8M+516.9% | -$1.5M-112.1% |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.
CRIS Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | N/A | N/A | 1724.0% | -218.0% | -300.1% | -426.8% | -268.9% | -360.5% |
| Net Margin | N/A | N/A | 1700.9% | -243.4% | -312.6% | -446.0% | -287.5% | -344.3% |
| Return on Equity | -182.8% | -190.4% | 354.4% | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -45.2%-15.8pp | -81.5%-54.5pp | 96.9%+120.3pp | -28.0%-4.2pp | -29.4%-6.0pp | -27.0%-7.8pp | -23.3%-8.2pp | -23.8%-10.2pp |
| Current Ratio | 0.49-0.3x | 1.11-0.1x | 0.49-0.9x | 0.70-0.5x | 0.74-1.0x | 1.23-2.8x | 1.39-1.4x | 1.22-4.1x |
| Debt-to-Equity | 3.04 | 1.34 | 2.66 | N/A | N/A | N/A | N/A | N/A |
| Asset Turnover | 0.00-0.1x | 0.00-0.1x | 0.060.0x | 0.110.0x | 0.090.0x | 0.060.0x | 0.080.0x | 0.070.0x |
Not reported in any period shown, so not listed: Gross Margin, FCF Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.
Note: The current ratio is below 1.0 (0.49), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Curis Inc CRIS | FY2025 | $9.4M | -$7.6M | -80.3% | $1.8M | 42/100 |
| Akari Therapeutics plc AKTX | FY2025 | N/A | -$17.3M | N/A | $20.4M | — |
| FibroBiologics, Inc. FBLG | FY2025 | N/A | -$18.6M | N/A | $8.2M | — |
| CytoMed Therapeutics Limited GDTC | FY2025 | $252K | -$3.1M | N/A | $12.1M | — |
| Q32 Bio Inc. QTTB | FY2025 | $53.7M | $29.8M | 55.5% | $249.2M | 67/100 |
Where Curis Inc Ranks
Frequently Asked Questions
What is Curis Inc's annual revenue?
Curis Inc (CRIS) reported $9.4M in total revenue for fiscal year 2025. This represents a -13.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Curis Inc's revenue growing?
Curis Inc (CRIS) revenue declined by 13.4% year-over-year, from $10.9M to $9.4M in fiscal year 2025.
Is Curis Inc profitable?
No, Curis Inc (CRIS) reported a net income of -$7.6M in fiscal year 2025, with a net profit margin of -80.3%.
What is Curis Inc's EBITDA?
Curis Inc (CRIS) had EBITDA of -$5.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Curis Inc's operating margin?
Curis Inc (CRIS) had an operating margin of -60.5% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Curis Inc's net profit margin?
Curis Inc (CRIS) had a net profit margin of -80.3% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Curis Inc's return on equity (ROE)?
Curis Inc (CRIS) has a return on equity of -138.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Curis Inc's operating cash flow?
Curis Inc (CRIS) recorded an outflow of $27.2M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Curis Inc's total assets?
Curis Inc (CRIS) had $20.0M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Curis Inc spend on research and development?
Curis Inc (CRIS) invested $28.3M in research and development during fiscal year 2025.
What is Curis Inc's current ratio?
Curis Inc (CRIS) had a current ratio of 0.49 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Curis Inc's debt-to-equity ratio?
Curis Inc (CRIS) had a debt-to-equity ratio of 2.66 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Curis Inc's return on assets (ROA)?
Curis Inc (CRIS) had a return on assets of -38.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Curis Inc's P/E ratio?
Curis Inc (CRIS) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $1.8M as of Oct 7, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Curis Inc's price-to-sales ratio?
Curis Inc (CRIS) trades at 0.4x sales, its market capitalization divided by revenue of $4.3M revenue, trailing 12 months to June 30, 2026. The market capitalization is $1.8M as of Oct 7, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Curis Inc's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Curis Inc (CRIS) held $5.1M in cash, cash equivalents and investments, and reported an operating cash outflow of $27.2M over that year. Dividing the one by the other, the reported balance equals about 2 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Curis Inc's Altman Z-Score?
Curis Inc (CRIS) has an Altman Z-Score of -88.29, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Curis Inc's Piotroski F-Score?
Curis Inc (CRIS) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Curis Inc's earnings high quality?
Curis Inc (CRIS) reported a net loss of $7.6M while operations used $27.2M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Curis Inc?
Curis Inc (CRIS) scores 42 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.